316810-07-8

Upstream product

• 5348-42-5 4,5-Dichloro-1,2-phenylenediamine 
• 619-66-9 4-Carboxybenzaldehyde 
• 723299-75-0 4-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)benzonitrile 

Downstream Products

• 1374777-48-6 2-(4-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)benzamido)-5-(4-(4-fluorobenzyl)piperidine-1-carbonyl)benzoic acid 
• 1374779-25-5 methyl 2-(4-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)benzamido)-5-(4-(4-fluorobenzyl)piperidine-1-carbonyl) benzoate 
• 1374640-03-5 N-(4-chlorophenyl)-4-(4-(5,6-dichloro-1H-benzo[d]imidazol-2-yl)benzamido)-2-hydroxybenzamide 

Relevant academic research and scientific papers

HETEROARYL RHEB INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same. Compositions comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of the compound in compositions of this invention is such that it is effective to measurably inhibit Rheb, in a biological sample or in a patient.

NOVEL NEUROTRYPSIN INHIBITORS

The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R1 is phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by

NEUROTRYPSIN INHIBITORS

The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is -CONR3R4,-NR5COR6, -NHR7, -OR8, -mR9, -CH2NRI0R11, -(CH2)2-R12, -CH=CH-R12, -C=C-R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer?s disease, and as cognitive enhancers.

Synthesis and antimicrobial activity of some novel 2-[4-(substituted piperazin-/piperidin-1-ylcarbonyl)phenyl]- 1 H-benzimidazole derivatives

In this study, we report the synthesis and antimicrobial evaluation of several new 4-(1H-benzimi-dazol-2-yl)benzamides (11 - 30) and 5-chloro-1-(p-fluorobenzyl)-2-{4-[(4-methylpiperazin-1-yl)carbonyl]phenyl} -1H-benzimidazole (33). Compound 20 exhibited the best antibacterial activity with MIC value of 6.25 μg/mL against Staphylococcus aureus and methicillin-resistant Staphylococcus aureus (MRSA). Significant antifungal activities were obtained with the compounds 13, 14, 18, 19, and 33 with MIC values of 3.12 μg/mL which are close to fluconazole.

Azolylbenzamides and analogues and their use for treating osteoporosis

A compound of formula (I) or a salt thereof, or a solvate thereof, wherein: X represents oxygen, sulphur, or NRb; Y and Z each independently represent nitrogen, CH, CR1 or CR2; A represents an unsubstituted or substituted aryl group or an unsubstituted or substituted heterocyclyl group; Ra represents —C(O)NRsRt; R1 and R2 each independently represents hydrogen or specific substituents; and the use of such a compound in the treatment and/or prophylaxis of diseases associated with over activity of osteoclasts in mammals.

Synthesis and potent antimicrobial activity of some novel 4-(5,6-dichloro-7H-benzimidazol-2-yl)-N-substituted benzamides

A series of 4-(5,6-dichloro-1H-benzimidazol-2-yl)-N-substituted benzamides were synthesized and evaluated for antibacterial and antifungal activities against Staphylococcus aureus, methicillin-resistant S. aureus (MRSA), methicillin-resistant S. epidermis